Business Context and Reporting Period
Company: Assembly Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 18, 2015 (Event Date: March 19, 2015)
Context: The company entered into a material definitive agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Specific metrics include:
- Shares Offered: 5,555,555 shares of common stock.
- Offering Price: $13.50 per share.
- Expected Net Proceeds: Approximately $75 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 833,333 shares.
- Underwriters: Credit Suisse Securities (USA) LLC and William Blair & Company, L.L.C. (Joint book-running managers).
Note: The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of an underwriting agreement to raise capital. This represents a significant increase in the company's equity capital base upon closing. The offering is expected to close on or about March 24, 2015, subject to customary closing conditions.
Guidance, Outlook, and Risks
Management Commentary: The company announced the launch and pricing of the offering via press releases on March 18 and March 19, 2015. The offering is made pursuant to an effective shelf registration statement (Form S-3) filed in November 2014.
Risks and Contingencies: The closing of the transaction is contingent upon the satisfaction of customary conditions contained in the underwriting agreement. The agreement includes standard representations, warranties, indemnification obligations, and termination provisions.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 24, 2015).
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 833,333 shares.
- Review the final prospectus supplement for any changes to the use of proceeds or offering terms.
- Check subsequent filings for the actual net proceeds received versus the estimated $75 million.